Bibliography
- Evans WE , McLeodHL: Pharmacogenomics – drug disposition, drug targets, and side effects.N. Engl. J. Med.348(6), 538–549 (2003).
- Evans WE , RellingMV: Moving towards individualized medicine with pharmacogenomics.Nature429(6990), 464–468 (2004).
- Frueh FW , GurwitzD: From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community.Pharmacogenomics5(5), 571–579 (2004).
- Kirchheiner, J , FuhrU, BrockmollerJ: Pharmacogenetics-based therapeutic recommendations – ready for clinical practice?Nature Rev. Drug Discov.4(8), 639–647 (2005).
- Breckenridge A , LindpaintnerK, LiptonP, McLeodH, RothsteinM, WallaceH: Pharmacogenetics: ethical problems and solutions.Nature Rev. Genet.5(9), 676–680 (2004).
- Knoppers BM , ChadwickR: Human genetic research: emerging trends in ethics.Nature Rev. Genet.6(1), 75–79 (2005).
- Lunshof, JE : Personalized medicine: How much can we afford? A bioethics perspective.Personalized Med.2(1), 43–47 (2005).
- Hopkins MM , IbarretaD, GaisserS et al.: Putting pharmacogenetics into practice.Nature Biotechnol.24(4), 403–410 (2006).
- Phillips KA , Van Bebber SL: A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics5(8), 1139–1149 (2004).
- Perlis RH , GanzDA, AvornJ et al.: Pharmacogenetic testing in the clinical management of schizophrenia: a decision–analytic model.J. Clin. Psychopharmacol.25(5), 427–434 (2005).
- Kroll ME , DraperGJ, StillerCA, Murphy MF: Childhood leukemia incidence in Britain, 1974–2000: time trends and possible relation to influenza epidemics. J. Natl Cancer Inst.98(6), 417–420 (2006).
- Coulthard SA , MathesonEC, HallAG, HogarthLA:The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. Nucleosides Nucleotides Nucleic Acids23(8–9), 1385–1391 (2004).
- Philips FS , SternbergSS, HamiltonS, ClarkeDA: The toxic effects of 6-mercaptopurine and related compounds.Ann. NY Acad. Sci.60(2), 283–296 (1954).
- Fulginiti VA , ScribnerR, GrothCG et al.: Infections in recipients of liver homografts.N. Engl. J. Med.279(12), 619–626 (1968).
- Lennard L , GibsonBE, NicoleT, Lilleyman JS: Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch. Dis. Child69(5), 577–579 (1993).
- Krynetski EY , SchuetzJD, GalpinAJ, Pui CH, Relling MV, Evans WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl Acad. Sci. USA92(4), 949–953 (1995).
- McLeod HL , RellingMV, LiuQ, PuiCH, EvansWE: Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia.Blood85(7), 1897–1902 (1995).
- Andersen JB , SzumlanskiC, Weinshilboum RM, Schmiegelow K: Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr.87(1), 108–111 (1998).
- Tai HL , KrynetskiEY, YatesCR et al.: Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet.58(4), 694–702 (1996).
- El-Azhary RA : Azathioprine: current status and future considerations.Int. J. Dermatol.42(5), 335–341 (2003).
- Ford LT , CooperSC, LewisMJ, BergJD: Reference intervals for thiopurine S-methyltransferase activity in red blood cells using 6-thioguanine as substrate and rapid non-extraction liquid chromatography.Ann. Clin. Biochem.41(Pt 4), 303–308 (2004).
- Cheung ST , AllanRN: Mistaken identity: misclassification of TPMT phenotype following blood transfusion.Eur. J. Gastroenterol. Hepatol.15(11), 1245–1247 (2003).
- Flowers CR , VeenstraD: The role of cost-effectiveness analysis in the era of pharmacogenomics.Pharmacoeconomics22(8), 481–493 (2004).
- Veenstra DL , HigashiMK, PhillipsKA: Assessing the cost-effectiveness of pharmacogenomics.AAPS PharmSci.2(3), E29 (2000).
- Phillips KA , VeenstraD, Van Bebber S, Sakowski J: An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics. Pharmacogenomics4(3), 231–239 (2003).
- Tavadia SM , MydlarskiPR, ReisMD et al.: Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J. Am. Acad. Dermatol.42(4), 628–632 (2000).
- Marra CA , EsdaileJM, AnisAH: Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.J. Rheumatol.29(12), 2507–2512 (2002).
- Winter J , WalkerA, ShapiroD, GaffneyD, SpoonerRJ, MillsPR: Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.Aliment Pharmacol. Ther.20(6), 593–599 (2004).
- Oh KT , AnisAH, BaeSC: Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea.Rheumatology (Oxford)43(2), 156–163 (2004).
- Gold M , SiegelJ, RussellL, WeinsteinM: Cost-effectiveness in health and medicine. Oxford University Press, New York, NY, USA (1996).
- Collie-Duguid ES , PritchardSC, Powrie RH et al.: The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics9(1), 37–42 (1999).
- Ameyaw MM , Collie-DuguidES, Powrie RH, Ofori-Adjei D, McLeod HL: Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum. Mol. Genet.8(2), 367–370 (1999).
- Sanderson J , AnsariA, MarinakiT, DuleyJ: Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?Ann. Clin. Biochem.41(Pt 4), 294–302 (2004).
- Colombel JF , FerrariN, DebuysereH et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.Gastroenterology118(6), 1025–1030 (2000).
- Ansari A , HassanC, DuleyJ et al.: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.Aliment Pharmacol. Ther.16(10), 1743–1750 (2002).
- Schwab M , SchaffelerE, MarxC et al.: Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.Pharmacogenetics12(6), 429–436 (2002).
- Viscomi S , PastoreG, DamaE et al.: Life expectancy as an indicator of outcome in follow-up of population-based cancer registries: the example of childhood leukemia.Ann. Oncol.17(1), 167–171 (2006).
- Oostenbrink J , BouwmansC, KoopmanschapM, RuttenF: Handbook for Costing Research. Methods and Guideline Prices for Economic Evaluations in Health. Health Care Insurance Board, Amstelveen, the Netherlands. Actualized version (2004).
- Church GM : Genomes for all.Sci. Am.294(1), 46–54 (2006).
- Kurzawski M , DziewanowskiK, Gawronska-SzklarzB, DomanskiL, DrozdzikM: The impact of thiopurine S-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients.Ther. Drug Monit.27(4), 435–441 (2005).
- To E rr Is Human. Building a Safer Health System. Committee on Quality of Health Care in America. Institute of Medicine. In: Institute of Medicine Report. Kohn L, Corrigan J, Donaldson M (Eds), National Academy Press, Washington, DC, USA (1999).
- Pirmohamed M , JamesS, MeakinS et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients.BMJ329(7456), 15–19 (2004).
- Dormann H , NeubertA, Criegee-RieckM et al.: Readmissions and adverse drug reactions in internal medicine: the economic impact.J. Intern. Med.255(6), 653–663 (2004).
- Gurwitz D , WeizmanA, RehaviM: Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine.Trends Pharmacol. Sci.24(3), 122–125 (2003).
- Gurwitz D , LunshofJE, DedoussisG et al.: Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.Pharmacogenomics J.5(4), 221–225 (2005).
- Baars, MJ , HennemanL, Ten Kate LP: Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: a global problem. Genet. Med.7(9), 605–610 (2005).
Websites
- Institute for Prospective Technological Studies (IPTS) website. www.jrc.es
- Institute for Prospective Technological Studies (IPTS) Report. Pharmacogenetics and Pharmacogenomics: State-of-the-art and potential socio-economic impacts in the EU. www.jrc.es/home/pages/detail.cfm?prs=1387
- Prometheus Laboratories TPMT genotyping test. www.prometheuslabs.com/212a.asp?nav=products
- Guide to the Methods of Technology Appraisal. National Institute for Clinical Excellence (NICE) 2003. www.nice.org.uk/pdf/methodologyconsultationdraftfinal.pdf